These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18666851)

  • 21. Obesity and atherogenic dyslipidemia.
    Bamba V; Rader DJ
    Gastroenterology; 2007 May; 132(6):2181-90. PubMed ID: 17498511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular basis of obesity and the risk for cardiovascular disease.
    Soufi M; Sattler AM; Herzum M; Maisch B; Schaefer JR
    Herz; 2006 May; 31(3):200-6. PubMed ID: 16770555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity and dyslipidemia.
    Franssen R; Monajemi H; Stroes ES; Kastelein JJ
    Med Clin North Am; 2011 Sep; 95(5):893-902. PubMed ID: 21855698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity; epiphenomenon or cause of metabolic syndrome?
    Lois K; Young J; Kumar S
    Int J Clin Pract; 2008 Jun; 62(6):932-8. PubMed ID: 18479286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome.
    Després JP
    Exerc Sport Sci Rev; 1997; 25():271-300. PubMed ID: 9213095
    [No Abstract]   [Full Text] [Related]  

  • 29. Obesity and dyslipidemia.
    Franssen R; Monajemi H; Stroes ES; Kastelein JJ
    Endocrinol Metab Clin North Am; 2008 Sep; 37(3):623-33, viii. PubMed ID: 18775355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance in chronic uremia.
    Guarnieri G; Zanetti M; Vinci P; Cattin MR; Barazzoni R
    J Ren Nutr; 2009 Jan; 19(1):20-4. PubMed ID: 19121765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting cardiovascular risk: early identification of insulin resistance.
    Fortson J; Howe L; Harmon C; Sherrill WW
    J Am Acad Nurse Pract; 2008 Jun; 20(6):319-25. PubMed ID: 18588659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
    Watts GF; Ooi EM; Chan DC
    Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dyslipidemia of diabetes and insulin resistance].
    Halimi S
    Nephrologie; 2000; 21(7):345-6. PubMed ID: 11200607
    [No Abstract]   [Full Text] [Related]  

  • 36. Chromium in metabolic and cardiovascular disease.
    Hummel M; Standl E; Schnell O
    Horm Metab Res; 2007 Oct; 39(10):743-51. PubMed ID: 17952838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity, insulin resistance and kidney disease risk: insights into the relationship.
    Sarafidis PA
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):450-6. PubMed ID: 18695384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of adiponectin in obesity, diabetes, and cardiovascular disease.
    Kawano J; Arora R
    J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.